Revolution Medicines (RVMD) Stock News
$RVMD · NASDAQ · 7 stories in 30 days$195.50
1D +7.33%1W −6.22%1M −9.64%
BORSA has published 7 stories on Revolution Medicines (RVMD) in the past 30 days. BORSA’s news read on RVMD is bullish at 61/100, −2 over 24 hours, based on 4 company events over the past 7 days. RVMD last closed at $177.96 on Oct 16, down 6.22% over five sessions and down 9.64% over the past month. Revolution Medicines’ next earnings report is scheduled for Wednesday, Nov 4.
The wire on $RVMD
newest first · updated · direct subject stories onlyRevolution Medicines Shares Rise After Phase 3 Zoldonrasib Trial Begins
Revolution Medicines began treating patients in a Phase 3 trial of zoldonrasib in combination with pembrolizumab and chemotherapy for first-line metastatic RAS G12D non-squamous NSCLC. Shares rose 6.8% to $194.46.
bullish 70 · impact 40Revolution Medicines begins Phase 3 trial for Zoldonrasib in combination therapy
Revolution Medicines has started treating patients in the Phase 3 RASolve 308 trial.
neutral 50 · impact 40
